SCHEMBL1779898

SCHEMBL1779898

N#Cc1ccc(N2CCC3(CCNCC3)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 9/20 0.65
USP2 O75604 7/20 0.65
TP53 P04637 4/20 0.53
KDM4E B2RXH2 1/20 0.53
TSHR P16473 9/20 0.50
CYP3A4 P08684 8/20 0.50
ALDH1A1 P00352 6/20 0.50
MAPK1 P28482 4/20 0.50
HSD17B10 Q99714 4/20 0.50
CYP1A2 P05177 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
KCNH2 Q12809 1/20 0.47
CYP2C19 P33261 4/20 0.45
HPGD P15428 3/20 0.45
CYP2C9 P11712 3/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CHRNA10 Q9GZZ6 1/20 0.45
CHRNA9 Q9UGM1 1/20 0.45
DRD2 P14416 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2819190 0.90 USP2 (0.53) CYP2D6USP2TP53KDM4ETSHR
SCHEMBL21393004 0.90 CYP2D6 (0.55) CYP2D6USP2TP53KDM4ETSHR
SCHEMBL32688287 0.87 TP53 (0.53) CYP2D6USP2TP53KDM4ETSHR
SCHEMBL22919201 0.85 TSHR (0.64) CYP2D6USP2TP53KDM4ETSHR
SCHEMBL231077 0.82 KDM4E (0.63) TP53KDM4EALDH1A1CHRNA10CHRNA9
SCHEMBL6956744 0.82 KDM4E (0.63) TP53KDM4EALDH1A1CHRNA10CHRNA9
SCHEMBL22914774 0.81 KCNH2 (0.54) CYP2D6USP2TP53KDM4ETSHR
Hydrochloric Acid SCHEMBL23303443 0.80 KDM4E (0.61) TP53KDM4EALDH1A1CHRNA10CHRNA9
Hydrochloric Acid SCHEMBL376202 0.80 KDM4E (0.61) TP53KDM4EALDH1A1CHRNA10CHRNA9
SCHEMBL13050532 0.79 CYP2D6 (0.69) CYP2D6USP2TP53KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943630-B2 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-05-17 US claimed
EP-1917264-B1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-17 EP claimed
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors ANIONA APS (DK) 2009-04-30 US claimed
EP-1917264-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-05-07 EP claimed
WO-2007000463-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO claimed
US-7943630-B2 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-05-17 US disclosed
EP-1917264-B1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-17 EP disclosed
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors ANIONA APS (DK) 2009-04-30 US disclosed
EP-1917264-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-05-07 EP disclosed
WO-2007000463-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 CYP2D6 183/4885USP2 2018/4885TP53 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.